Core Viewpoint - Daiichi Sankyo announced that Enhertu (injectable trastuzumab deruxtecan) has officially received approval from the National Medical Products Administration (NMPA) in China for second-line treatment of HER2-positive adult patients with gastric or gastroesophageal junction adenocarcinoma [1] Group 1: Approval and Indications - The new indication marks the sixth approval for trastuzumab deruxtecan in China and the second indication related to HER2-positive gastric cancer [1] - This approval signifies that trastuzumab deruxtecan is the first and only approved antibody-drug conjugate (ADC) for second-line treatment in this patient population in China [1] Group 2: Development and Clinical Trials - Trastuzumab deruxtecan is designed to target HER2 and is a DXd antibody-drug conjugate developed and commercialized by Daiichi Sankyo in collaboration with AstraZeneca [1] - The approval for the new gastric cancer indication is based on results from the international multicenter, randomized, open-label Phase III study DESTINY-Gastric04, which demonstrated statistically significant and clinically meaningful improvements in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) [1]

Core Viewpoint - The approval of Datroway, a TROP2-targeted antibody-drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca, marks a significant advancement in the treatment of HR-positive, HER2-negative breast cancer in China, addressing a critical need in the oncology market [1][1][1] Group 1: Product Approval - Datroway has received approval from the National Medical Products Administration (NMPA) in China for treating adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously undergone endocrine therapy and at least one line of chemotherapy [1][1][1] - This drug is the second ADC utilizing Daiichi Sankyo's proprietary DXd technology to be approved in China, highlighting the company's innovative capabilities in drug development [1][1][1] Group 2: Market Context - Breast cancer is the second most common malignant tumor among women in China, with approximately 357,000 new cases and 75,000 deaths reported in 2022, indicating a significant public health concern [1][1][1] - About 70% of diagnosed breast cancer cases are classified as HR-positive and HER2-negative, which underscores the importance of targeted therapies like Datroway in addressing this patient population [1][1][1]